Company: BDRX
Filing Date: 2025-04-29
Form Type: POS AM
Source: 0001214659-25-006581
Chunk: 117

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-04-29
Form: POS AM
Chunk 117
---
 credit purposes.

| 72 |

<div align='center'>SELLING SHAREHOLDER</div>

This prospectus relates to the possible resale from time to time by
the Selling Shareholder of any or all of the Ordinary Shares (represented by Depositary Shares) that may be issued by us to the Selling
Shareholder under the Purchase Agreement. Such shares of include (i) up to 33,413,549 Purchase Shares that we may elect, in our sole discretion,
to issue and sell to the Selling Shareholder, from time to time from and after the Commencement Date under the Purchase Agreement; and
(ii) up to 721,651 Commitment Shares that may be issued to the Selling Shareholder in connection with related issuances and sales of Purchase
Shares to release the Company of its liability to pay the Commitment Fee as consideration for the Selling Shareholder’s execution
and delivery of the Purchase Agreement.

As used in this prospectus,
the term “Selling Shareholder” includes the Selling Shareholder listed in the table below, and its permitted pledgees,
donees, transferees, assignees, successors, designees, successors-in-interest and others who later come to hold any of the Selling Shareholder’s
interest in the securities in accordance with the terms of the applicable agreements governing their respective registration rights, other
than through a public sale. This prospectus also covers any additional securities that may become issuable by reason of stock splits,
stock dividends or other similar transactions.

For additional information
regarding the issuance of the securities covered by this prospectus, see the section entitled “Committed Equity Financing”
above. We are registering the securities pursuant to the provisions of the Purchase Agreement and the Registration Rights Agreement in
order to permit the Selling Shareholder to offer the shares for resale from time to time. Except for the transactions contemplated by
the Purchase Agreement and the Registration Rights Agreement or as otherwise set forth in this prospectus, the Selling Shareholder has
not had any material relationship with us within the past three years.

The table below presents information regarding the Selling Shareholder
and the securities that it may offer from time to time under this prospectus. This table is prepared based on information supplied to
us by the Selling Shareholder, and reflects holdings as of April 1, 2025. The number of shares in the column “Maximum Number of
Ordinary Shares to be Offered Pursuant to this Prospectus” represents all of the Ordinary Shares (represented by Depositary Shares)